Rituximab in Patients with the Steroid-Resistant Nephrotic Syndrome
Open accessThe DOI matches its Crossref record.
Abstract
To the Editor: The treatment of patients with the steroid-resistant nephrotic syndrome (SRNS) is challenging. Persistent proteinuria and hypoalbuminemia result in serious complications and progressive kidney disease. Intensive treatment regimens show varying results in inducing remission but are associated with adverse effects. On the basis of suggestions that B lymphocytes are crucial in the pathogenesis of the nephrotic syndrome,1 we examined the efficacy of treatment with rituximab, a monoclonal antibody against CD20 antigen, in patients with SRNS that was resistant to treatment with high-dose corticosteroids, alkylating agents, and calcineurin inhibitors. Five patients (three with initial resistance and two with late . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
on behalf of the International Pediatric Nephrology Association, Trautmann, A., Vivarelli, M., Samuel, S., Gipson, D., Sinha, A., Schaefer, F., Hui, N. K., Boyer, O., Saleem, M. A., et al. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04519-1 · Cited by 389
Self-citationTrautmann, A., Boyer, O., Hodson, E., Bagga, A., Gipson, D. S., Samuel, S., Wetzels, J., Alhasan, K., Banerjee, S., Bhimma, R., et al. (2023) · Pediatric Nephrology · doi:10.1007/s00467-022-05739-3 · Cited by 292
Self-citationSong, Q.-Q., Xie, W.-Y., Tang, Y.-J., Zhang, J., & Liu, J. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0151 · Cited by 40
Metadata
- Authors
- Bagga, A., Sinha, A., & Moudgil, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-28
- Volume
- 356
- Issue
- 26
- Pages
- 2751-2752
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2030581712
- Cited by
- 172
- References
- 0
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.